Compare OGI & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGI | LUCD |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.3M | 192.9M |
| IPO Year | 2015 | 2021 |
| Metric | OGI | LUCD |
|---|---|---|
| Price | $0.93 | $0.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.39 | ★ $4.00 |
| AVG Volume (30 Days) | 447.7K | ★ 1.7M |
| Earning Date | 08-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,346,000.00 |
| Revenue This Year | $34.95 | $33.93 |
| Revenue Next Year | $30.97 | $165.18 |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $0.85 | $0.50 |
| 52 Week High | $2.24 | $1.63 |
| Indicator | OGI | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 34.74 | 22.17 |
| Support Level | $0.92 | N/A |
| Resistance Level | $1.07 | $1.09 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 15.67 | 0.69 |
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.